Solid Biosciences Stock: The Bull Case Is No Longer Just Duchenne (NASDAQ:SLDB)
· seekingalpha.com
Solid Biosciences is transitioning from a speculative Duchenne gene therapy play to a multi-asset rare disease platform. Find out why SLDB stock is a buy.
My bullish outlook on Solid Biosciences ( SLDB ) is based on investors still viewing the company primarily as a speculative Duchenne gene therapy opportunity. H...